# Delaware Crossing Investor Group

> Delaware Crossing Investor Group is a VC fund backing Health Care. See 15 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Doylestown, United States
- Total investments: 15
- Last investment: Sep 2024
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/delaware-crossing-investor-group/
- Website: http://www.delawarecrossing.org

Delaware Crossing Investor Group is a network of former and current executives and entrepreneurs who provide counsel and capital to early-stage and other growth-oriented companies.Delaware Crossing Investor Group is a membership organization of qualified investors who play an active role in the sourcing of prospective portfolio companies,managing the investment process and serving on the board of directors of portfolio companies.

## Contacts

5 contacts available for Delaware Crossing Investor Group. Shizune tracks 18 team members at Delaware Crossing Investor Group. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/delaware-crossing-investor-group?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 27% |
| Biotechnology | 4 | 27% |
| Manufacturing | 3 | 20% |
| Software | 2 | 13% |
| Therapeutics | 2 | 13% |

35 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 7 | 47% |
| Series A | 3 | 20% |
| Funding Round | 2 | 13% |
| Pre-Seed | 1 | 7% |
| Convertible Note | 1 | 7% |

6 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Antonio Tedesco | Partner | 0 | https://shizune.co/investors/profile/antonio-tedesco |
| Michael Murphy | Member | 0 | https://shizune.co/investors/profile/michael-murphy |
| Richard Woodbridge | Member | 0 | https://shizune.co/investors/profile/richard-woodbridge |
| Cristian A. Ossa | Member | 0 | https://shizune.co/investors/profile/cristian-a-ossa |
| Dave Wurz | Member | 0 | https://shizune.co/investors/profile/dave-wurz |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Vytala | Vytala is a food tech firm focused on improving nutrition through innovative solutions. |  | Pre-Seed | Sep 19, 2024 |  |
| Measure Studio | Measure Studio is an engine designed to create a social media content strategy that is informed by data. Digital publishers, companies, agencies, and influencers may consolidate and analyze their social media data using the company's engine in order to create better content. The engine offers a safe environment for managing social mediaanalytics. |  | Seed | Apr 21, 2023 |  |
| SunRay Scientific Inc. | SunRay Scientific (SRS) is a supplier of advanced materials for printed electronics manufacturing and lead free packaging. The company’s key focus is the advancement of green electronics with clean chemistry, which includes development of conductive inks, epoxies and anisotropic conductive adhesives that minimize waste, eliminate use of lead, andreduce carbon footprint in electronics manufacturing. | $2.5M | Venture - Series Unknown | Sep 06, 2022 |  |
| Vesteck Inc. | VESTECK, Inc. (WWW.VESTECK.com) is an early-stage medical device company focused on bringing their proprietary technology to the aortic repair, structural heart and GI markets. Their first product, the "Suture-Tight" nitinol suture delivery catheter will bring a novel technology to endovascular aortic repair market solving a significantglobal challenge for physicians and patients. | $4.3M | Series A | Aug 25, 2021 |  |
| Ophidion | Ophidion is a biotechnology company that delivers a central nervous system therapeutics to targeted sites in the brain. The company uses a Trojan horse strategy to exploit an endogenous receptor-mediated transport system to deliver small molecule drugs and biologics into the brain. They are currently focused on developing a pipeline to delivergene-silencing therapies to treat neurodegenerative diseases, including diseases of Cognitive Impairment (e.g. Alzheimer’s disease, Parkinson’s disease) as well as Huntington’s disease.Ophidion platform technology is amenable to delivering multiple classes of drugs, including small molecules and macromolecules (gene therapeutics, siRNA’s, antibodies, peptides, and other macromolecules). It also has an advanced program that is positioned to start pivotal clinical trials to treat anxiety-related disorders, together with a patented companion biomarker diagnostic to select the appropriate patient population. | $1.7M | Seed | Oct 03, 2019 |  |
| ThruPore Technologies | ThruPore Technologies' makes heterogeneous catalysts in pellets and powders. The company provides superior heterogeneous catalysts, initially for reactions using palladium on carbon. | $540K | Seed | Feb 21, 2018 |  |
| Tobly | Tobly is a B2B equipment rental marketplace built for multi-site facilities managers. | $497K | Convertible Note | Jul 20, 2017 |  |
| OnlySky | Only Sky provides a white-label, customizable platform where ski area guests craft their ideal experience on the ski area's website. Ski area staff can manage all inventory, eCommerce, POS commerce, ski school, and events from the same platform. No upfront fees and great ease of use make it an obvious choice for independent ski areas in NorthAmerica, and snow schools around the world. | $340K | Seed | Jun 07, 2017 |  |
| Life.io | Life.io is the world’s first web-based platform specifically designed to help people make better decisions every moment, to take care of themselves more, to engage more, to simply live more. Delivered through insurance companies or employers, it’s always on, sharing inspired ideas on how to live better today and every day after. | $1.5M | Seed | Jan 12, 2016 |  |
| Annovis Bio | Annovis Bio is specialty pharmaceutical company founded to develop novel treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders. The company has two compounds in clinical development: Posiphen® targets early stage AD and PD and may stop or slow the progression of the disease; BNC targets late stageAD and may stabilize the decline. | $5.7M | Series A | May 26, 2015 |  |

10 of 15 investments shown.

## Co-investors
- [Robin Hood Ventures](https://shizune.co/investors/profile/robin-hood-ventures) — VC Fund, 11 deals together
- [Ben Franklin Technology Partners of Southeastern Pennsylvania](https://shizune.co/investors/profile/ben-franklin-technology-partners-of-southeastern-pennsylvania) — VC Fund, 2 deals together
- [BioAdvance](https://shizune.co/investors/profile/bioadvance) — VC Fund, 2 deals together
- [Jumpstart New Jersey Angel Network](https://shizune.co/investors/profile/jumpstart-new-jersey-angel-network) — VC Fund, 2 deals together
- [Mid Atlantic Angel Fund](https://shizune.co/investors/profile/mid-atlantic-angel-fund) — VC Fund, 2 deals together
- [5AM Ventures](https://shizune.co/investors/profile/5am-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Delaware Crossing Investor Group invest in?

Delaware Crossing Investor Group invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Seed and Series A stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Delaware Crossing Investor Group?

Public channels for Delaware Crossing Investor Group include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Delaware Crossing Investor Group?

The team at Delaware Crossing Investor Group includes Antonio Tedesco (Partner), Michael Murphy (Member) and Richard Woodbridge (Member), among 18 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co